SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing substantial upward momentum, driven by record-breaking inflows into its spot ETFs, signaling robust institutional interest and increasing demand. The community is actively discussing a potential decoupling from Bitcoin's price action and an emerging narrative of a supply squeeze due to decreasing exchange holdings. This has fueled widespread bullish sentiment and anticipation of continued market adoption.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus (MNTS) is trending following news of developing a 3D-printed fuel tank for its Vigoride-7 Orbital Service Vehicle, positioning it as an innovator in the burgeoning space sector. Community sentiment is mixed, with some anticipating a significant short squeeze due to high short interest and low float, while others express concern over a recent private placement and potential dilution impacting shareholder value.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is experiencing significant upward momentum following its announcement of 4D LiDAR integration within the NVIDIA DRIVE Hyperion platform ecosystem. This major collaboration has ignited widespread excitement within the community, with many anticipating a substantial short squeeze and sustained bullish movement. Investors are closely monitoring AEVA's potential as a key player in the evolving LiDAR and autonomous vehicle sector, amplified by its association with NVIDIA.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a focal point of discussion as the competitive landscape for obesity treatments heats up, driven by the recent introduction of Novo Nordisk's oral GLP-1 and its aggressive pricing. Community sentiment is sharply divided between those who believe Viking's pipeline assets, including its oral formulation, remain highly competitive in a vast market, and others who express concern about management's M&A strategy given the evolving competitive pressures. Amidst this, speculation about potential strategic partnerships or acquisitions continues to circulate widely.

What is the project about? Vara Network is a substrate-based future proof smart contract platform that is fast, scalable, and makes it simple to create and deploy next-generation Web3.0 dApps Vara is the first standalone network in the Gear Protocol  Gear is a next-gen cloud infrastructure platform providing most intuitive and frictionless environment for web2 and web3 developers to build complex infrastructure solutions and disruptive dApps for any ecosystem  What makes your project unique? Vara is built upon three core concepts: The actor model, and persistent memory — two widely adopted primitives from massive computation and microservices architecture spaces  Wasm — a WebAssembly-based virtual machine that runs on all modern browsers. Proven to be faster than any alternative web2 virtual machines  Vara was created to serve as a wasm-native hub for innovative protocols that leverage parallel execution and asynchronous programming to deliver leading decentralized products in any segment  History of your project. Gear Protocol and the Vara Network were originally created by Nikolay Volf, one of the core developers of Polkadot. In 2021, he embarked on building an advanced layer 1 smart contract platform using Substrate, Polkadot's custom framework. His vision included creating a platform that enables fast and efficient execution of robust, feature-rich dApps while in a seamless development environment similar to that of Web 2.0 development. He did this by  harnessing the power of innovative technologies like Wasm, the Actor Model, and Persistent Memory. These technologies significantly enhance smart contract development and provide a seamless end-user experience and provide the foundation for the development of Vara Network.  1. Q2 2021 - Pre-Seed Round: In the second quarter of 2021, the Protocol secured its initial funding through a pre-seed round. This likely involved seeking investment from early-stage investors or venture capitalists to kickstart the development of the project.  2. Q4 2021 - Seed Round: In December 2021 raised $12 Million in Venture Round. Private investment round led by Blockchange Venture. In addition to Blockchange, other top venture capital funds participated in this round, including Three  Arrows Capital, Lemniscap, Distributed Global, LAO, Mechanism Capital, Bitscale, Spartan Group LLC, HashKey, DI Ventures, Elysium Venture Capital, Signum Capital and P2P Economy lead by Konstantin Lomashuk, along with a number of top executives of Web3 Foundation and Parity Technologies. Dr. Gavin Wood, Founder and ex-CEO of Parity Technologies and one of the key individual investors participating in this round.  3. 2022 - Intensive Scaling and Development, First Test Integrations: Throughout the year 2022, Vara was focused on two primary activities. First, the engagement in an extensive outreach process to build up the team. Second, the project advanced its technical development efforts and started working on integrating their technology with various test environments to ensure its functionality and viability.  4. Q4 2022 - Testnet Launch.   5. Q1 2023 - PoA Launch: In the first quarter of 2023, Vara achieved launch of its Proof of Authority (PoA) consensus network, which is a chain candidate for mainnet.  Current Status of Vara:  Presently, the project boasts a talented and diverse decentralized workforce, consisting of dozens of engineers and other community members  to drive the project's success.  One of the remarkable aspects of Vara is its substantial pipeline of initiatives with over 40 projects.  What’s next for your project? Current projects being researched and developed by the community:  - Intensive testing and improvement of the actor model features in the blockchain space  - Launch of the key stack of dApps in our parallel and asynchronous environment   - Development of innovative infrastructure solutions (e.g offchain zk actors including machine learning) independently and together with the segment leaders  What can your token be used for? VARA tokens maintain core utility features required for the network to operate: transaction fees staking and network security governance other: gas pools for gas reservation  Contributors to the Gear protocol are exploring the mechanics of how to distribute a portion of block rewards directly toward dApp developers

Vara Network

Vara Network is currently trending with heightened community interest, driven by recent listings on new exchanges like MEXC and BitMart, alongside a significant increase in trading volume. Discussions are vibrant around its utility as a Layer 1 network, featuring an AI-integrated exchange and cross-chain bridging technology, leading many to anticipate substantial gains within the broader crypto market, while also noting continued debate over its tokenomics and perceived undervaluation.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending following its strategic collaboration with OpenAI, integrating advanced AI models into its Athena marketing platform. This news has sparked active community debate, with many expecting significant growth and seeing the stock as undervalued, though some remain cautious about similar industry AI integrations and upcoming events.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending on heightened anticipation for the January 7th Congressional hearing, "American Energy Dominance: Dawn of the New Nuclear Era," and a crucial Department of Energy announcement regarding surplus plutonium allocation. The community widely expects Oklo to secure this vital fuel for its Aurora reactors, a move seen as essential for accelerating its role in powering AI data centers and achieving commercialization, especially given the current Energy Secretary's past involvement with the company. Significant bullish sentiment, unusual options activity, and the potential for a short squeeze are driving active investor discussion and positioning, despite some pre-revenue skepticism.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences (SLS) is experiencing intense bullish momentum, largely driven by its sustained trading above the critical $5 threshold, which is attracting institutional attention. The community is actively discussing the potential of its GPS immunotherapy to revolutionize AML treatment through extended patient survival, fueling expectations for a substantial revaluation or potential buyout. This positive sentiment is further amplified by extremely high borrow fees, limited short availability, and Reg SHO status, leading to widespread short and gamma squeeze speculation among traders.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending following Nvidia's announcement of an open-source autonomous driving platform and 2027 robotaxi plans, which has fueled significant community debate about its competitive moat. Amidst a recent "Sell" rating from UBS and ongoing concerns about declining EV sales, many are questioning Tesla's financial health and market leadership, while some bulls still anticipate a rebound despite increasing competitive pressures.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened attention following its listing on Robinhood and the delisting of its futures contracts on Binance, which the community views as removing price manipulation and unlocking its growth potential. Enthusiasts are actively accumulating during dips, anticipating further upside as the Goliath Mainnet launch and Chain's ISO 20022 upgrade suggest increasing institutional readiness and potential for a broader altcoin market rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Pharmaceutical Stocks To Follow Now - January 5th

Eli Lilly and Company, Novo Nordisk A/S, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly...

Best Medical Stocks To Follow Now - January 5th

Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, Johnson & Johnson, Thermo Fisher Scientific, AbbVie, and Pfizer are the seven Medical stocks to watch today, according to MarketBeat's...

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices starting near $5 a day and broad pharmacy and telehealth access.read more...

LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?

LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.

LifeMD Adds Novo Nordisk's Weight-loss Pill Wegovy To Telehealth Platform

(RTTNews) - LifeMD, Inc. (LFMD), a provider of virtual primary care and pharmacy services, on Monday said it is now offering Novo Nordisk's Wegovy pill for chronic weight management and...

Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?

Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.

Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in...

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.

The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose...

<ul class="summary-bullets"><li>However, the price of the 4 mg dose will rise to $199 a month from April 15, 2026, the company said.</li><li>There are no promotional offers on the 9 mg and 25 mg doses of Wegovy, which will cost $299 per month.</li><li>Novo Nordisk also stated that customers with commercial insurance can get the oral Wegovy pill for as low as $25 per month.</li></ul>Novo Nordisk AS (NVO) on Monday announced that customers in the U.S. can get the oral Wegovy pill starting at $149 a month.The company stated on its website that the 1.5 mg and 4 mg doses of Wegovy will be available to self-paying customers at these prices beginning January 5. However, the cost of the 4 mg dose will rise to $199 a month from April 15, 2026.There are no promotional offers on the 9 mg and 25 mg doses of Wegovy, which will cost $299 per month.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were up nearly 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Retail Warns Shorts</h2>Retail users on the platform were divided following the announcement of the price of the oral Wegovy pill.One bullish user stated that “it’s time to give up” for investors who are short on Novo, expecting the stock to rise by around 13% in the coming weeks.<stembedurl>https://stocktwits.com/Bargainhunters/message/640795872</stembedurl>Another user asked: Although Eli Lilly &amp; Co. (LLY) is a “beast,” why doesn't it have a weight-loss pill yet?<stembedurl>https://stocktwits.com/TopWaterSniper/message/640791970</stembedurl><h2 class="st-heading-2">Wegovy For As Low As $25</h2>Novo Nordisk also stated that customers with commercial insurance can get the oral Wegovy pill for as low as $25 per month.For comparison, the injectable version comes in doses ranging from 0.25 mg to 2.4 mg, at a standard price of $349 per month. Novo is currently running a limited-period offer that brings down the price of the 0.25 mg and 0.5 mg doses to $199 a month for the first two months, only for new patients.<h2 class="st-heading-2">FDA Approval</h2>This comes after Novo Nordisk received approval from the U.S. Food and Drug Administration, making it the first oral version of a GLP-1 drug to be approved by the federal agency.“The pill is here. With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Novo Nordisk CEO Mike Doustdar in December.The company stated that it has applied for approval of the oral Wegovy pill in a 25 mg dose to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025.<h2 class="st-heading-2">Taking On Zepbound</h2>Novo Nordisk’s Wegovy is now available, starting at $149 a month and rising to $349 a month for the injectable version.For comparison, Eli Lilly’s Zepbound is currently available for $349 a month for the 2.5 mg dose for uninsured patients. Prices go up to $1,049 a month for the highest dose of 15 mg, according to the company.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is up 2% year-to-date, but down 40% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-shipments-fell-7-2025-despite-december-surge/cmxMSsjR4bj">Tesla China Shipments Reportedly Fell 7% In 2025 Despite A December Surge, Days After Losing Largest EV Maker Crown To BYD</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’

The 1.5 mg and 4 mg doses of Wegovy will be available to self-paying customers at these prices beginning January 5.

Equity

Novo Nordisk A/S $NVO Position Increased by Allen Wealth Management LLC

Allen Wealth Management LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 960.2% during the third quarter, according to the company in its most recent filing with the SEC. The...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.92	--	--	N/A
Q3 '25	$0.75	$0.69	-7.91%	MISSED
Q2 '25	$0.92	$0.93	1.42%	BEAT
Q1 '25	$0.91	$0.99	9.16%	BEAT
Q4 '24	$0.83	$0.89	6.80%	BEAT

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NVO News

NVONovo Nordisk A/S